These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36383903)

  • 21. [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
    Sternschuss M; Sarfaty M
    Harefuah; 2022 Jan; 161(1):49-54. PubMed ID: 35077061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 23. Antibody-drug conjugates for the treatment of urothelial carcinoma.
    Ravi P; McGregor BA
    Expert Opin Biol Ther; 2021 Jul; 21(7):915-922. PubMed ID: 32589063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-Drug Conjugates in Uro-Oncology.
    Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
    Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
    Grimm MO; Foller S; Leeder M; Leucht K
    Urologie; 2023 Jul; 62(7):679-684. PubMed ID: 37294330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.
    Faltas B; Goldenberg DM; Ocean AJ; Govindan SV; Wilhelm F; Sharkey RM; Hajdenberg J; Hodes G; Nanus DM; Tagawa ST
    Clin Genitourin Cancer; 2016 Feb; 14(1):e75-9. PubMed ID: 26541586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
    Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
    Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
    Tarantino P; Carmagnani Pestana R; Corti C; Modi S; Bardia A; Tolaney SM; Cortes J; Soria JC; Curigliano G
    CA Cancer J Clin; 2022 Mar; 72(2):165-182. PubMed ID: 34767258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
    Kim JH; Chang IH
    Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
    Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
    Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-drug conjugates in solid tumors: a look into novel targets.
    Criscitiello C; Morganti S; Curigliano G
    J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-Drug Conjugates in Bladder Cancer.
    Vlachostergios PJ; Jakubowski CD; Niaz MJ; Lee A; Thomas C; Hackett AL; Patel P; Rashid N; Tagawa ST
    Bladder Cancer; 2018 Jul; 4(3):247-259. PubMed ID: 30112436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy.
    You X; Zhu C; Yu P; Wang X; Wang Y; Wang J; Yu J; Wang K
    Biomed Pharmacother; 2024 Feb; 171():116152. PubMed ID: 38228034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
    Hashimoto H; Tanaka Y; Murata M; Ito T
    Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.
    Cabaud O; Berger L; Crompot E; Adélaide J; Finetti P; Garnier S; Guille A; Carbuccia N; Farina A; Agavnian E; Chaffanet M; Gonçalves A; Charafe-Jauffret E; Mamessier E; Birnbaum D; Bertucci F; Lopez M
    Mol Cancer Ther; 2022 Jul; 21(7):1227-1235. PubMed ID: 35534238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants.
    Fan Y; Li Q; Shen Q; Liu Z; Zhang Z; Hu S; Yu W; He Z; He Q; Zhang Q
    Front Oncol; 2022; 12():858865. PubMed ID: 35515131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.
    Ghose A; Lapitan P; Apte V; Ghosh A; Kandala A; Basu S; Parkes J; Shinde SD; Boussios S; Sharma A; Das P; Vasdev N; Rebuzzi SE; Ürün Y; Kanesvaran R; Maniam A; Banna GL
    Curr Oncol Rep; 2024 Jun; 26(6):633-646. PubMed ID: 38652426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
    Atiq S; Hirshman N; Shariff A; Zhang T
    Urol Oncol; 2023 Oct; 41(10):410-419. PubMed ID: 34973855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.